糖原合成酶激酶-3抑制剂在骨质疏松性疾病治疗中的作用研究进展

Research progress of the treatment on osteoporotic disease with glycogen synthase kinase-3 inhibitor

骨质疏松症是一种全身性代谢性疾病,其主要特征为骨密度降低,易引发骨质疏松性骨折等疾病。糖原合成酶激酶-3抑制剂能够抑制糖原合成酶激酶-3活性,从而促进Wnt信号转导通路及其下游基因、蛋白的表达,主要通过促进骨髓间充质干细胞、成骨细胞增殖和分化的同时抑制破骨细胞活性,共同调节骨细胞微环境来实现对骨质疏松性疾病的治疗。现就糖原合成酶激酶-3抑制剂在骨质疏松性疾病治疗过程中的作用研究进展做一综述。

Osteoporosis is a systemic metabolic disease.Its main character is the reduction of bone mineral density,which easily leads to osteoporotic fractures.Glycogen synthase kinase-3 inhibitor can inhibit glycogen synthase kinase-3 activity,thereby promoting the expression of Wnt-channel and its downstream genes and proteins.It mainly promotes the proliferation and differentiation of bone marrow mesenchymal stem cells and osteoblasts,while inhibits the activity of osteoclasts.It regulates bone cell microenvironment to achieve the treatment of osteoporotic disease.Now we review the research progress of glycogen synthase kinase-3 inhibitor in the treatment of osteoporotic disease.